• Optimized Sulfonamides Target TB with Reduced CYP 2C9 Inhibi

  2026-07-22

  This study systematically optimized sulfaphenazole-derived sulfonamides for potent activity against Mycobacterium tuberculosis while minimizing unwanted CYP 2C9 inhibition. The findings reveal structure–activity insights and identify lead compounds promising for safer anti-TB regimens.

• Preserving Post-Translational Integrity in Sepsis Research

  2026-07-22

  This thought-leadership article explores the strategic imperative of controlling proteolysis and dephosphorylation during protein extraction—highlighted by emerging mechanistic insights into HMGB1 modification in macrophage-driven sepsis. It integrates evidence from recent literature, including the pivotal role of lactate in regulating HMGB1 release, and offers actionable guidance for translational researchers. The discussion centers on the mechanistic, workflow, and translational benefits of using a Protease and Phosphatase Inhibitor Cocktail (EDTA Free, 100X in ddH2O), with a focus on maximizing fidelity in post-translational modification (PTM) studies, competitive benchmarking, and clinical translation.

• EdU Flow Cytometry Assay Kits (Cy5): Precision in S-Phase DN

  2026-07-21

  The EdU Flow Cytometry Assay Kits (Cy5) empower researchers with a rapid, multiplex-compatible approach for cell proliferation analysis, leveraging advanced click chemistry for precise S-phase DNA synthesis detection. This guide details optimized workflows, real-world troubleshooting, and the strategic impact of this technology in translational cancer and immunotherapy research.

• Bile Acid Retention Suppresses Antigen Presentation in MASH-

  2026-07-21

  The referenced study reveals a mechanistic link between bile acid retention and impaired antigen presentation in MASH-associated hepatocellular carcinoma (HCC). By elucidating the GPR120–bile acid–NLRC5 pathway, the work highlights a novel targetable axis driving immune evasion and resistance to immunotherapy, with implications for designing combination strategies to restore tumor immunogenicity.

• Gut-Brain Cholinergic Signaling and Antiseizure Effects of B

  2026-07-20

  Jia et al. uncover a gut-brain cholinergic pathway by which Bacteroides fragilis suppresses seizures, supported by both animal models and a clinical trial in pediatric refractory epilepsy. Their work establishes a mechanistic link between microbiota composition, enhanced acetylcholine neurotransmitter signaling, and seizure control, with translational implications for microbiota-targeted therapies.

• Transcranial K+-Selective Channelrhodopsin: Noninvasive Seiz

  2026-07-20

  This study introduces HcKCR1-hs, a highly light-sensitive, K+-selective channelrhodopsin, enabling noninvasive transcranial optogenetic inhibition of epileptic activity in mouse models. The findings represent a significant advance in neural silencing technologies, with implications for safer therapeutic strategies in neurological disorders.

• GCG Disrupts SARS-CoV-2 Nucleocapsid Phase Separation and Re

  2026-07-19

  This study uncovers that SARS-CoV-2 nucleocapsid protein (N) undergoes RNA-triggered liquid–liquid phase separation (LLPS), a process critical for viral assembly and replication. The authors show that the natural compound (-)-gallocatechin gallate (GCG) disrupts N protein LLPS and inhibits viral replication, highlighting a novel antiviral mechanism and a potential therapeutic direction.

• Strategic RNA Probe Labeling: Translational Impact & Mechani

  2026-07-18

  This thought-leadership article explores the mechanistic and strategic imperatives of high-yield Cy5 RNA probe synthesis for translational research. It contextualizes the HyperScribe™ T7 High Yield Cy5 RNA Labeling Kit within the evolving landscape of RNA-centric diagnostics and therapeutics, integrating mechanistic insights, competitive analysis, and actionable protocol guidance. By bridging advances in in vitro transcription with emerging mRNA delivery technologies, the piece delivers nuanced recommendations for maximizing sensitivity, specificity, and translational value in molecular workflows.

• Staurosporine: Broad-Spectrum Serine/Threonine Kinase Inhibi

  2026-07-17

  Staurosporine is a potent, broad-spectrum serine/threonine protein kinase inhibitor with nanomolar activity against multiple kinase targets. It is widely employed as an apoptosis inducer in cancer cell line research and for dissecting kinase-mediated signaling pathways. Quantitative inhibition of VEGF receptor autophosphorylation and robust anti-angiogenic effects underpin its value in translational oncology.

• Type III Collagen’s Tumor-Restrictive Role in Breast Cancer

  2026-07-17

  This study reveals that type III collagen (Col3) within the breast cancer microenvironment acts as a tumor-restrictive matrix component, limiting cancer cell proliferation and metastasis. The findings suggest that enhancing Col3 could be a promising strategy to improve prognosis and develop novel therapies for breast cancer patients.

• FGFR3 Inhibition with NVP-BGJ398 Improves SLC26A2 Chondrodys

  2026-07-16

  This study demonstrates that pharmacological inhibition of FGFR3 signaling with NVP-BGJ398 phosphate can alleviate skeletal defects in a mouse model of SLC26A2-related chondrodysplasia. The findings provide key genetic and translational evidence for targeting FGFR3 in rare skeletal disorders, offering new avenues for therapeutic intervention beyond oncology.

• 1,2-Dioleoyl-3-trimethylammonium-propane chloride in Gene De

  2026-07-16

  DOTAP empowers high-efficiency nucleic acid delivery in functional genomics and immunometabolic modulation. Explore stepwise workflows, advanced experimental applications, and troubleshooting insights that will maximize success in both routine and innovative lipid nanoparticle studies.

• HyperPFU™ High-Fidelity DNA Polymerase: Practical PCR Guidan

  2026-07-15

  HyperPFU™ high-fidelity DNA polymerase enables robust, low-error PCR amplification of long, GC-rich, or otherwise challenging DNA templates. It should be selected for workflows requiring accurate, blunt-ended DNA products, but is not suitable for applications relying on 3'-A overhangs or sticky-end ligation.

• AS1842856: Precision Foxo1 Inhibition for Translational Meta

  2026-07-15

  This article explores the mechanistic and translational power of AS1842856, a potent Foxo1 inhibitor, in modulating MSC fate through the PI3K-Akt-Foxo1 pathway. By integrating recent mechanistic studies, validated workflows, and emerging clinical implications, it provides strategic guidance for researchers in metabolic disease and bone health. The discussion highlights how AS1842856 advances beyond standard tools, offering unique precision for dissecting gluconeogenesis, autophagy, and stem cell activation.

• Nutlin-3a (SKU A3671): Reliable MDM2 Inhibitor for p53 Pathw

  2026-07-14

  This evidence-based guide analyzes how Nutlin-3a (SKU A3671) from APExBIO addresses common laboratory challenges in cell viability, proliferation, and cytotoxicity assays. Using scenario-driven Q&As, the article demonstrates Nutlin-3a's reproducible performance, validated protocol flexibility, and robust p53 pathway activation for cancer research workflows.

16459 records 1/1098 page Next 12345 下5页 Last page